Pharma Clinical S.A.G. (2003) Ltd. was involved in the following sample of international studies, 5 of them were managed from Israel (marked with asterisk), 2 of them were cardiovascular outcome studies of 800 patients each.
Following is the distribution of clinical studies according to indication:
| Field |
Indication |
Number of
Patients
|
Number of Sites
|
% of
Commitment
|
% Of total patients in study |
| Cardiovascular |
* Ischemic heart disease outcome study |
872 |
17 |
174% |
11.4% |
| |
Ischemic heart disease progression of coronary calcification |
571 |
1 |
142% |
100% |
| |
Coronary Endothelial Function |
17 |
3 |
68% |
3.7% |
| |
Myocardial infarction outcome study |
650 |
17 |
130% |
18% |
| |
Erectile dysfunction |
35 |
3 |
70% |
2.5% |
| |
Congestive heart failure |
547 |
18 |
144% |
26% |
| |
Pulmonary hypertention |
28 |
2 |
175% |
3.5% |
| Anti infectives |
Hospital acquired pneumonia |
31 |
7 |
69% |
19% |
| |
Intra-abdominal infections |
92 |
6 |
115% |
16% |
| |
Community acquired pneumonia |
57 |
6 |
95% |
10% |
| |
* Skin and skin Structure infections |
109 |
6 |
168% |
13% |
| Oncology |
* Non small cell Lung cancer |
8 |
3 |
50% |
8% |
| |
Colorectal carcinoma |
24 |
3 |
120% |
43% |
| |
* Primary Hepatoma |
27 |
6 |
135% |
20% |
| |
* Phase I- interaction study |
48 |
1 |
NA |
100% |
| |
Breast cancer |
6 |
5 |
40% |
7.5% |
| Hematology |
Prevention of thromboembolic phenomena events |
60 |
4 |
100% |
9% |
| |
Deep vein thrombosis |
61 |
7 |
122% |
10% |
| CNS |
Stroke |
79 |
8 |
158% |
14% |
| |
Prevention of stroke |
233 |
9 |
90% |
2.5% |
